Therapeutics News and Research

RSS

Experimental drug may be twice as good at fighting vision loss as previously thought

In studies with lab-grown human cells and in mice, Johns Hopkins Medicine researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.

11 Apr 2019

Human iPSCs-derived mesenchymal stem cells could avoid ageing-related shortfalls

The use of primary mesenchymal stem cells is fraught with ageing-related shortfalls such as limited expansion and early senescence.

11 Apr 2019

Scientists develop technique to clear abnormal tau protein from human neurons

Harnessing a probe used to image the brain in diagnosing Alzheimer's disease and related forms of dementia, scientists at Dana-Farber Cancer Institute and Massachusetts General Hospital have successfully cleared patient-derived brain cells of an abnormal protein associated with dementia and other neurogenerative disorders.

10 Apr 2019

Can someone tell me what a PBM does?

It was back-to-school day at the Senate Finance Committee hearing Tuesday morning. In the third of a series of hearings on rising drug prices, the senators seemed focused on getting an answer to one central question: What the heck is a pharmacy benefit manager?

10 Apr 2019

Common food preservative could make flu vaccine less effective

A preservative commonly used to increase the shelf life of food products may weaken the body’s immune defense against influenza, thus reducing the response to the flu vaccine.

9 Apr 2019

Cancer vaccine injected into tumour could kill all cancer cells

Researchers have developed an experimental cancer vaccine that when injected into a single tumour can help trigger the immune system to kill the cancer cells circulating within the body. The results of the study titled, “Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination,” were published in the latest issue of the journal Nature Medicine, this week, Monday.

9 Apr 2019

Scientists identify receptor responsible for bitter taste of Epsom salt

A team of scientists headed by Maik Behrens from the Leibniz-Institute for Food Systems Biology at the Technical University of Munich has identified the receptor responsible for the bitter taste of various salts. These include medically used Epsom salt.

8 Apr 2019

New clinical trials to investigate combination immunotherapy for treating advanced cancers

City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.

8 Apr 2019

Study finds no statistically significant effect of drug shortages on cancer treatment

For the vast majority of cancer drugs experiencing shortages over a seven-year period, a new USC research study found no statistically significant effect of shortages on chemotherapy treatment.

8 Apr 2019

Celltrion and iProgen Biotech announce partnership for development of novel ADCs

On April 8, Celltrion and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER2 and CD20.

8 Apr 2019

Patients on immunotherapies should consume more fiber, fewer probiotics

A new study has found that taking probiotics could drastically reduce the response of cancer patients to immunotherapy. Patients on a fiber-rich diet showed a five-fold increase in response.

5 Apr 2019

Inauguration of NIDD, the Neuroimmunology Drug Development Summit

NIDD is the industry’s first meeting dedicated to targeting neuroimmunological mechanisms in order to develop clinically efficacious therapeutics.

From Neuroimmunology Drug Development 5 Apr 2019

$Reformulated epileptic drug reaches first clinical trial for medically refractory epilepsy$

Reformulated epileptic drug reaches first clinical trial for medically refractory epilepsy

A currently approved epileptic drug to treat seizures has been modified by a University of Colorado Anschutz Medical Campus professor and is currently being used in a clinical trial in Australia for medically refractory epilepsy.

4 Apr 2019

Researchers unravel 3D structure of key molecular target for cancer treatment

Columbia University scientists, in collaboration with researchers from Nimbus Therapeutics, have demystified a metabolic enzyme that could be the next major molecular target in cancer treatment.

4 Apr 2019

UB researchers develop new method to more accurately predict tumor growth rates

University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.

4 Apr 2019

New computational model of human kinase may provide insights for cancer drug development

Researchers have developed a computational model for human MEK1, a protein with potential as a drug target for a variety of human cancers.

4 Apr 2019

NIAID awards $22 million grant to develop antibody-based therapies against lethal viruses

The National Institute of Allergy and Infectious Diseases has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.

4 Apr 2019

Study provides insights on liver injury in men taking body building supplements

In a study reported in Alimentary Pharmacology & Therapeutics, 44 men with liver injury, attributed to over-the-counter bodybuilding supplements, experienced a uniform and distinctive pattern of signs and symptoms that were often prolonged, difficult to treat, and accompanied by disability and weight loss.

3 Apr 2019

Study suggests HLD200 could provide novel, more flexible alternative to treating ADHD

A new three-part study showed that a delayed-release, extended-release form of methylphenidate could be given to adults in the evening with or without food and would not exert any clinically meaningful effect for at least 10 hours after administration.

2 Apr 2019

Metrion Biosciences announces closure of funding round

Metrion Biosciences Ltd, the specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March.

From Metrion Biosciences Limited 2 Apr 2019

Therapeutics News and Research

Experimental drug may be twice as good at fighting vision loss as previously thought

Human iPSCs-derived mesenchymal stem cells could avoid ageing-related shortfalls

Scientists develop technique to clear abnormal tau protein from human neurons

Can someone tell me what a PBM does?

Common food preservative could make flu vaccine less effective

Cancer vaccine injected into tumour could kill all cancer cells

Scientists identify receptor responsible for bitter taste of Epsom salt

New clinical trials to investigate combination immunotherapy for treating advanced cancers

Study finds no statistically significant effect of drug shortages on cancer treatment

Celltrion and iProgen Biotech announce partnership for development of novel ADCs

Patients on immunotherapies should consume more fiber, fewer probiotics

Inauguration of NIDD, the Neuroimmunology Drug Development Summit

Reformulated epileptic drug reaches first clinical trial for medically refractory epilepsy

Researchers unravel 3D structure of key molecular target for cancer treatment

UB researchers develop new method to more accurately predict tumor growth rates

New computational model of human kinase may provide insights for cancer drug development

NIAID awards $22 million grant to develop antibody-based therapies against lethal viruses

Study provides insights on liver injury in men taking body building supplements

Study suggests HLD200 could provide novel, more flexible alternative to treating ADHD

Metrion Biosciences announces closure of funding round

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News